Bardy Diagnostics, Inc. Sustainability Profile
Bardy Diagnostics, Inc., commonly referred to as BardyDx, is a pioneering company headquartered in the United States, specialising in innovative cardiac monitoring solutions. Founded in 2015, BardyDx has rapidly established itself within the medical technology industry, focusing on advanced diagnostic tools that enhance patient care and streamline clinical workflows. The company is renowned for its flagship product, the BardyDx Cardiac Patch, which offers continuous, non-invasive monitoring of cardiac activity. This unique device stands out for its ability to provide comprehensive data while ensuring patient comfort. With a commitment to improving cardiovascular health, BardyDx has achieved significant milestones, including regulatory approvals and partnerships that bolster its market position. As a leader in cardiac diagnostics, BardyDx continues to drive advancements that benefit both healthcare providers and patients alike.
DitchCarbon Score
How does Bardy Diagnostics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bardy Diagnostics, Inc.'s score of 33 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bardy Diagnostics, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Baxter International Inc., which may influence its climate commitments and emissions reporting. As of now, Bardy Diagnostics has not established any documented reduction targets or initiatives under the Science Based Targets initiative (SBTi). Additionally, there are no climate pledges or specific reduction initiatives reported. Emissions data and climate commitments may be inherited from its parent company, Baxter International Inc., which operates at a cascade level of three. This means that while Bardy Diagnostics may not have direct emissions data, it is part of a larger corporate family that may have its own climate strategies and performance metrics. In summary, Bardy Diagnostics, Inc. is currently in the process of aligning its climate commitments with its parent company's initiatives, but specific emissions data and reduction targets are not available at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2002 | 2003 | 2005 | 2006 | 2009 | 2010 | 2011 | 2014 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 781,365,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Bardy Diagnostics, Inc.'s Industry?
How Carbon Intensive is Bardy Diagnostics, Inc.'s Location?
Bardy Diagnostics, Inc.'s Scope 3 Categories Breakdown
Bardy Diagnostics, Inc.'s Scope 3 emissions, which decreased by 10% last year and decreased by approximately 7% since 2009, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 45% of Scope 3 emissions.
Top Scope 3 Categories
Bardy Diagnostics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bardy Diagnostics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
